The ability to downregulate DNA damage response, together with the inhibition of GC resistance-associated transcription factor RUNX2 [48], sets Menin-1 inhibition as an efficient strategy in infant B-ALL. This evidence concerns the gene RUNX2 and acute lymphoblastic leukemia.